BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
20. Dezember 2024 09:00 ET
|
BioAtla, Inc.
SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionally...
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
16. Dezember 2024 08:00 ET
|
BioAtla, Inc.
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with...
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
10. Dezember 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
07. November 2024 16:01 ET
|
BioAtla, Inc.
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of...
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
31. Oktober 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
04. Oktober 2024 09:05 ET
|
BioAtla, Inc.
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
01. Oktober 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
23. September 2024 07:30 ET
|
BioAtla, Inc.
Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and...
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
16. September 2024 08:00 ET
|
BioAtla, Inc.
An ongoing complete response (CR) with an overall response rate (ORR) of 32% achieved across two dosing regimens Underscores ozuriftamab vedotin’s activity in a high unmet need SCCHN patient...
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
09. September 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...